Autocrine prolactin as a promoter of mammary tumour growth

Journal of Dairy Research

Volumn 72, Issue SPEC. ISS., 2005, Pages 58-65

  Manhes, Caroline ^a   Goffin, Vincent ^a   Kelly, Paul A ^a   Touraine, Philippe ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Antagonist; Autocrine; Dopamine; Mammary tumour; Prolactin

Indexed keywords

PROLACTIN; PROLACTIN RECEPTOR;

ANIMAL; BREAST TUMOR; CELL DIVISION; CHEMISTRY; DIMERIZATION; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL NEOPLASM; HUMAN; MOUSE; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; BREAST NEOPLASMS; CELL DIVISION; DIMERIZATION; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; PROLACTIN; RECEPTORS, PROLACTIN;

EID: 24944563712     PISSN: 00220299     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0022029905001196     Document Type: Review

References (72)

1. Acosta JJ, Munoz RM, Gonzalez L, Subtil-Rodriguez A, Dominguez-Caceres MA, Garcia-Martinez JM, Calcabrini A, Lazaro-Trueba I & Martin-Perez J 2003 Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways. Molecular Endocrinology 17 2268-2282
2. Ahonen TJ, Harkonen PL, Laine J, Rui H, Martikainen PM & Nevalainen MT 1999 Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology 140 5412-5421
3. Baudhuin A, Manfroid I, Van De WC, Martial JA & Muller M 2002 Transcription of the human prolactin gene in mammary cells. Annals of the New York Academy of Sciences 973 454-458
4. Beck MT, Peirce SK & Chen WY 2002 Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R. Oncogene 21 5047-5055
5. Ben Jonathan N, Liby K, McFarland M & Zinger M 2002 Prolactin as an autocrine/paracrine growth factor in human cancer. Trends in Endocrinology and Metabolism 13 245-250
6. Ben-Jonathan N, Mershon JL, Allen DL & Steinmetz RW 1996 Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocrinology Reviews 17 639-669
7. Bernichtein S, Jeay S, Vaudry R, Kelly PA, Goffin V 2003a New homologous bioassays for human lactogens show that agonism or antagonism of various analogs is a function of assay sensitivity. Endocrine 20 177-190
8. Bernichtein S, Kayser C, Dillnerm K, Moulin S, Kopchick JJ, Martial JA, Norstedt G, Isaksson O, Kelly PA & Goffin V 2003b Development of pure prolactin receptor antagonists. Journal of Biological Chemistry 278 35988-35999
9. Bertucci F, Nasser V, Granjeaud S, Eisinger F, Adelaide J, Tagett R, Loriod B, Giaconia A, Benziane A, Devilard E, Jacquemier J, Viens P, Nguyen C, Birnbaum D & Houlgatte R 2002 Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. Human MolecularGenetics 11 863-872
10. Binart N, Helloco C, Ormandy CJ, Barra J, Clement-Lacroix P, Baran N & Kelly PA 2000 Rescue of preimplantatory egg development and embryo implantation in prolactin receptor-deficient mice after progesterone administration. Endocrinology 141 2691-2697
11. Biswas R & Vonderhaar BK 1987 Role of serum in the prolactin responsiveness of MCF-7 human breast cancer cells in long-term tissue culture. Cancer Research 47 3509-3514
12. Bole-Feysot C, Goffin V, Edery M, Binart N & Kelly PA 1998 Prolactin and its receptor: actions, signal transduction pathways and phenotypes observed in prolactin receptor knockout mice. Endocrinology Reviews 19 225-268
13. Boutin JM, Jolicoeur C, Okamura H, Gagnon J, Edery M, Shirota M, Banville D, Dusanter-Fourt I, Djiane J & Kelly PA 1988 Cloning and expression of the rat prolactin receptor, a member of the growth hormone/prolactin receptor gene family. Cell 53 69-77
14. Brockman JL, Schroeder MD & Schuler LA 2002 PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. Molecular Endocrinology 16 774-784
15. Brue T, Vallette S, Pellegrini-Bouiller I & Enjalbert A 1997 Congenital multiple anterior pituitary hormone deficiencies. An approach of pituitary ontogenesis. Annals of Endocrinology 58 436-450
16. Buskila D, Lorber M, Neumann L, Flusser D & Shoenfeld Y 1996 No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus. Journal of Rheumatology 23 629-632
17. Chen WY, Ramamoorthy P, Chen N, Sticca R & Wagner TE 1999 A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clinical Cancer Research 5 3583-3593
18. Clevenger CV, Chang WP, Ngo W, Pasha TM, Montone KT & Tomaszewski JE 1995 Expression of prolactin and prolactin receptor in human breast carcinoma. American Journal of Pathology 146 695-705
19. Clevenger CV, Furth PA, Hankinson SE & Schuler LA 2003 The role of prolactin in mammary carcinoma. Endocrinology Reviews 24 1-27
20. Clevenger CV & Plank TL 1997 Prolactin as an autocrine/paracrine factor in breast cancer. Journal of Mammary Gland. Biology and Neoplasia 2 59-68
21. Das R & Vonderhaar BK 1997 Prolactin as a mitogen in mammary cells. Journal of Mammary Gland Biology and Neoplasia 2 29-39
22. Freeman ME, Kanyicska B, Lerant A & Nagy G 2000 Prolactin: structure, function, and regulation of secretion. Physiological Reviews 80 1523-1631
23. Fuh G & Wells JA 1995 Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. Journal of Biological Chemistry 270 13133-13137
24. Ginsburg E & Vonderhaar BK 1995 Prolactin synthesis and secretion by human breast cancer cells. Cancer Research 55 2591-2595
25. Goffin V, Bernichtein S, Kayser C & Kelly PA 2003 Development of new prolactin analogs acting as pure prolactin receptor antagonists. Pituitary 6 89-95
26. Goffin V, Touraine P, Pichard C, Bernichtein S & Kelly PA 1999 Should prolactin be reconsidered as a therapeutic target in human breast cancer? Molecular and Cellular Endocrinology 151 79-87
27. Gutzman JH, Miller KK & Schuler LA 2004 Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 88 69-77
28. Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B & Speizer FE 1999 Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. Journal of the National Cancer Institute 91 629-634
29. Horseman ND, Zhao W, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle SJ, Smith F, Markoff E & Dorshkind K 1997 Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO Journal 16 6926-6935
30. Hu ZZ, Meng J & Dufau ML 2001 Isolation and characterization of two novel forms of the human prolactin receptor generated by alternative splicing of a newly identified exon 11. Journal of Biological Chemistry 276 41086-41094
31. Hughues LE 2000 Fibroadenomas and related tumors. In: Benign Disorders and Diseases of the Breast. Concepts and Clinical Management, (Eds LE Hughues, RE Mansel & DJT Webster) pp. 73-94. London: WB Saunders
32. Jara LJ, Gomez-Sanchez C, Silveira LH, Martinez-Osuna P, Vasey FB & Espinoza LR 1992 Hyperprolactinemia in systemic lupus erythematosus: association with disease activity. American Journal of Medical Science 303 222-226
33. Kelly PA, Bachelot A, Kedzia C, Hennighausen L, Ormandy CJ, Kopchick JJ & Binart N 2002 The role of prolactin and growth hormone in mammary gland development. Molecular and Cellular Endocrinology 197 127-131
34. Kinet S, Bernichtein S, Llovera M, Kelly PA, Martial JA & Goffin V 2001 Molecular basis of the interaction between human prolactin and its membrane receptor: a ten year study. Recent Research in Developmental Endocrinology 2 1-24
35. Liby K, Neltner B, Mohamet L, Menchen L & Ben Jonathan N 2003 Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth. Breast Cancer Research and Treatment 79 241-252
36. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A & Hennighansen L 1997 Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes and Development 11 179-186
37. Llovera M, Pichard C, Bernichtein S, Jeay S, Touraine P, Kelly PA & Goffin V 2000a Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene 19 4695-4705
38. Llovera M, Touraine P, Kelly PA & Goffin V 2000b Involvement of prolactin in breast cancer: redefining the molecular targets. Experimental Gerontology 35 41-51
39. Malet C, Gompel A, Yaneva H, Cren H, Fidji N, Mowszowicz I, Kuttenn F & Mauvais-Jarvis P 1991 Estradiol and progesterone receptors in cultured normal human breast epithelial cells and fibroblasts: immunocytochemical studies. Journal of Clinical Endocrinology and Metabolism 73 8-17
40. Maus MV, Reilly SC & Clevenger CV 1999 Prolactin as a chemoattractant for human breast carcinoma. Endocrinology 140 5447-5450
41. McMurray RW, Allen SH, Braun AL, Rodriguez F & Walker SE 1994 Longstanding hyperprolactinemia associated with systemic lupus erythematosus: possible hormonal stimulation of an autoimmune disease. Journal of Rheumatology 21 843-850
42. Meng J, Tsai-Morris CH & Dufau ML 2004 Human prolactin receptor variants in breast cancer: low ratio of short forms to the long-form human prolactin receptor associated with mammary carcinoma. Cancer Research 64 5677-5682
43. Mertani HC, Garcia-Caballero T, Lambert A, Gerard F, Palayer C, Boutin JM, Vonderhaar BK, Waters MJ, Lobie PE & Morel G 1998 Cellular expression of growth hormone and prolactin receptors in human breast disorders. International Journal of Cancer 79 202-211
44. Molitch ME 2002 Medical management of prolactin-secreting pituitary adenomas. Pituitary 5 55-65
45. Nandi S, Guzman RC & Yang J 1995 Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proceedings of the National Academy of Sciences of the USA 92 3650-3657
46. Naylor MJ, Lockefeer JA, Horseman ND & Ormandy CJ 2003 Prolactin regulates mammary epithelial cell proliferation via autocrine/paracrine mechanism. Endocrine 20 111-114
47. Neidhart M 1996 Elevated serum prolactin or elevated prolactin/cortisol ratio are associated with autoimmune processes in systemic lupus erythematosus and other connective tissue diseases. Journal of Rheumatology 23 476-481
48. Ormandy CJ, Hall RE, Manning DL, Robertson JF, Blamey RW, Kelly PA, Nicholson RI & Sutherland RL 1997 Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. Journal of Clinical Endocrinology and Metabolism 82 3692-3699
49. Pauzner R, Urowitz MB, Gladman DD & Gough JM 1994 Prolactin in systemic lupus erythematosus. Journal of Rheumatology 21 2064-2067
50. Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE & Holly JM 2004 Prolactin acts as a potent survival factor for human breast cancer cell lines. British Journal of Cancer 91 305-311
51. Pittius CW, Hennighausen L, Lee E, Westphal H, Nicols E, Vitale J & Gordon K 1988 A milk protein gene promoter directs the expression of human tissue plasminogen activator cDNA to the mammary gland in transgenic mice. Proceedings of the National Academy of Sciences of the USA 85 5874-5878
52. Reynolds C, Montone KT, Powell CM, Tomaszewski JE & Clevenger CV 1997 Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 138 5555-5560
53. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP & Schuler LA 2003 Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene 22 4664-4674
54. Ryska A, Reynolds C & Keeney GL 2001 Benign tumors of the breast with multinucleated stromal giant cells. Immunohistochemical analysis of six cases and review of the literature. Virchows Archives 439 768-775
55. Schroeder MD, Symowicz J & Schuler LA 2002 PRL modulates cell cycle regulators in mammary tumor epithelial cells. Molecular Endocrinology 16 45-57
56. Shaw-Bruha CM, Pirrucello SJ & Shull JD 1997 Expression of the prolactin gene in normal and neoplastic human breast tissues and human mammary cell lines: promoter usage and alternative mRNA splicing. Breast Cancer Research and Treatment 44 243-253
57. Topper YJ 1970 Multiple hormone interactions in the development of mammary gland in vitro. Recent Progress in Hormone Research 26 287-308
58. Touraine P & Kelly PA 1997 Physiologie de la prolactine et mécanismes d'action. In: Médecine de la Reproduction pp. 115-136 (Eds P Mauvais-Jarvis, G Schaison & P Touraine). Paris: Flammarion
59. Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, Nicolas A, Trivin C, Postel-Vinay MC, Kuttenn F & Kelly PA 1998 Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. Journal of Clinical Endocrinology and Metabolism 83 667-674
60. Trott JF, Hovey RC, Koduri S, Vonderhaar BK 2003 Alternative splicing to exon 11 of human prolactin receptor gene results in multiple isoforms including a secreted prolactin-binding protein. Journal of Molecular Endocrinology 30 31-47
61. Tworoger SS, Eliassen AH, Rosner B, Sluss P & Hankinson SE 2004 Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Research 64 6814-6819
62. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, Waxman DJ & Davey HW 1997 Requirement of Stat5b for Sexual dimorphism of body growth rates and liver gene expression. Proceedings of the National Academy of Sciences of the USA 94 7239-7244
63. Vomachka AJ, Pratt SL, Lockefeer JA & Horseman ND 2000 Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth. Oncogene 19 1077-1084
64. Vonderhaar BK 1998 Prolactin: the forgotten hormone of human breast cancer. Pharmacological Therapy 79 169-178
65. Vonderhaar BK 1999 Prolactin involvement in breast cancer. Endocrine-Related Cancer 6 389-404
66. Walker SE 2001 Treatment of systemic lupus erythematosus with bromocriptine. Lupus 10 197-202
67. Welsch CW, Lambrecht LK & Hassett CC 1977 Suppression of mammary tumorigenesis in C3H/He mice by ovariectomy or treatment with 2-bromo-alpha-ergocryptine: a comparison. Journal of the National Cancer Institute 58 1135-1138
68. Welsch CW & Nagasawa H 1977 Prolactin and murine mammary tumorigenesis: a review. Cancer Research 37 951-963
69. Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG & Tornell J 1997 Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. Journal of Clinical Investigation 100 2744-2751
70. Yamauchi T, Yamauchi N, Ueki K, Sugiyama T, Waki H, Miki H, Tobe K, Matsuda S, Tsushima T, Yamamoto T, Fujita T, Taketani Y, Fukayama M, Kimura S, Yazaki Y, Nagai R & Kadowaki T 2000 Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer. Journal of Biological Chemistry 275 33937-33944
71. Zargar AH, Masoodi SR, Laway BA, Shah NA & Salahudin M 1997 Familial puerperal alactogenesis: possibility of a genetically transmitted isolated prolactin deficiency. British Journal of Obstetrics and Gynaecology 104 629-631
72. Zargar AH, Salahuddin M, Laway BA, Masoodi SR, Ganie MA & Bhat MH 2000 Puerperal alactogenesis with normal prolactin dynamics: is prolactin resistance the cause? Fertility and Sterility 74 598-600